GLP-1 Medications Decrease Suicidal Thoughts Among Adolescents with Obesity
Study Overview
A comprehensive review of medical records from over 7,000 adolescents treated for obesity revealed promising results regarding GLP-1 medications. These medications, specifically semaglutide and liraglutide, were associated with a 33% lower risk of suicidal thoughts, affirming their potential for safe treatment.
Details of the Research
Conducted by researchers at Hadassah University Medical Center, the study covered patients aged 12 to 18, demonstrating that among those prescribed GLP-1 drugs, only 1.4% exhibited suicidal ideation over one year, significantly less than the 2.3% who received behavioral treatment.
- The study spanned medical records across 120 health-care organizations, primarily in the United States.
- Data showed no correlation between GLP-1 drug use and increased suicide attempts over a follow-up period of up to three years.
- Despite these findings, gastrointestinal side effects were more prevalent among those using the medications.
Expert Insights
Dr. Kitty O’Hare and Dr. Nora Volkow highlighted the need for ongoing monitoring of mental health for adolescents on these drugs, indicating that effective treatment for both obesity and mental health disorders should be considered. They stated that understanding the mental health impacts of these medications is crucial as adolescent obesity rates continue to escalate.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.